Background-The role of circulating homocysteine as an atherosclerosis risk factor has recently been questioned.
P lasma homocysteine is associated with cardiovascular risk 1, 2 and surrogate markers such as oxidative stress 3 and endothelial dysfunction. 4 However, the potential causative role of homocysteine in vascular disease pathogenesis remains unclear. 5, 6 Although homocysteine may have direct effects on important biological processes such as thrombosis and production of reactive oxygen species, 1,2,7 interpretation of these effects is confounded by corresponding changes in folate status. Low plasma folate levels are strongly associated with elevated plasma homocysteine, 8 and intervention studies to reduce homocysteine typically use folate supplementation. 9, 10 Recent evidence suggests that plasma folate may play important direct roles in the pathogenesis of atherosclerosis that are independent of homocysteine. 11 Indeed, 5-methyltetrahydrofolate (5-MTHF), the circulating form of folate, has a number of direct antiatherogenic effects by scavenging peroxynitrite radicals, 12 augmenting nitric oxide (NO) bioavailability, [13] [14] [15] and decreasing vascular superoxide generation in the vascular wall. 12 The potential beneficial effects of homocysteine lowering have been tested in recent clinical trials in patients with recent myocardial infarction, 9 stable coronary artery disease, 10 or stroke. 16 Homocysteine lowering was achieved by combined folate and B vitamin supplementation but with no effect on major clinical outcomes, 9, 10 perhaps except stroke. 10, 16 Thus, the primary value of homocysteine lowering, as distinct from folate supplementation, remains uncertain as a therapeutic strategy in cardiovascular risk reduction.
Clinical Perspective on p 2515
A widely known functional genetic polymorphism in the methyltetrahydrofolate reductase gene (MTHFR 677 CϾT) has been used as a marker of altered folate and homocysteine status to test causality of the folate-homocysteine pathway in relation to other known confounding factors or the effects of reverse causality. 17 The MTHFR 677 CϾT polymorphism is independently associated with vascular disease surrogates such as endothelial function 18 and intima-media thickness. 19 However, MTHFR 677 CϾT has effects on both folate and homocysteine that are difficult to separate, so it remains uncertain whether the primary importance of MTHFR 677 CϾT in cardiovascular disease is as a marker of constitutive reduction in 5-MTHF or as a constitutive increase in homocysteine levels. This uncertainty results in part from incomplete understanding of the mechanistic relationships between levels of 5-MTHF and homocysteine in both plasma and the vascular wall and how each relates to endothelial function and reactive oxygen species production.
We used the MTHFR 677CϾT polymorphism as a model of constitutive alteration of 5-MTHF biosynthesis to investigate functional differences between primary alterations in 5-MTHF and secondary alterations in homocysteine in vascular disease pathophysiology. We examined the effects of this polymorphism on 5-MTHF and total homocysteine (tHcy) levels in both plasma and vascular tissue, vascular NO-mediated endothelial function, and vascular superoxide production in patients with coronary artery disease. Our findings indicate that vascular 5-MTHF levels, rather than vascular or plasma tHcy levels, are the most important determinant of endothelial function and vascular oxidative stress. We suggest that plasma tHcy is a secondary marker of vascular folate status rather than a primary therapeutic target. These findings are important for interpreting the results of previous clinical trials and refining future therapeutic strategies.
Methods

Study Subjects
We studied 218 patients with coronary artery disease undergoing elective coronary artery bypass grafting surgery at the John Radcliffe Hospital, Oxford, UK. Exclusion criteria were any inflammatory, infective, liver, or renal disease; malignancy; acute coronary event during the last 2 months; or clinically overt heart failure. Patients receiving nonsteroidal antiinflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins also were excluded. Individual characteristics of the patients are presented in Table 1 . Importantly, there was no significant difference in the demographic characteristics and medication between the patients in the 3 MTHFR genotype groups or between the overall population and the subgroups of patients in whom samples of saphenous vein (SV) and internal mammary artery (IMA) were available (Tables 1 and II , respectively, of the online Data Supplement). The study was approved by the local Research Ethics Committee, and each patient gave written informed consent.
Plasma and Tissue Samples
Blood samples were obtained immediately before surgery after overnight fasting. Samples were centrifuged at 2500 rpm for 10 minutes, and serum or plasma was stored at Ϫ80°C until assayed. Samples of SV and IMA were obtained at the time of coronary artery bypass grafting surgery as previously described. 12 Paired vessel segments were snap-frozen and stored at Ϫ80°C for measurement of tHcy and 5-MTHF content or were transferred to the laboratory for functional studies within 30 minutes in ice-cold Krebs-Henseleit buffer. 12 
DNA Extraction and Genotyping
Genomic DNA was extracted from 2 mL whole blood using standard methods (QIAamp DNA Blood Midi Kit, Qiagen, Germantown, Md). The MTHFR 677CϾT polymorphism (database of single nucleotide polymorphisms, rs1801133) was genotyped using the Amplifluor SNP Genotyping System (Chemicon, Watford, UK) and with the primers and assay conditions previously described. 20 The genotype frequencies were in accordance with Hardy-Weinberg equilibrium in both the overall population and the subsets of patients from whom SV and IMA samples were obtained. There was no significant difference in genotype distribution between the overall population and those subjects for whom SV and IMA samples were available (Table III of the online Data Supplement). Furthermore, there were no significant differences in the genotype frequencies between the overall population and the subsets of patients from whom SV and IMA samples were obtained.
Determination of Vascular Superoxide Production
Vascular superoxide production was measured in paired segments of IMA using lucigenin-enhanced chemiluminescence as previously described. 12 Vessels were opened longitudinally to expose the endothelial surface and equilibrated for 20 minutes in oxygenated ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers. Continuous variables are expressed as meanϮSD.
(95% O 2 /5% CO 2 ) Krebs-HEPES buffer (pH 7.4) at 37°C. Lucigenin-enhanced chemiluminescence was measured with lowconcentration lucigenin (5 mol/L). 12 As a measure of endothelial NO synthase (eNOS) coupling, we determined NOS-derived superoxide production, which was estimated as the difference in superoxide production after 20 minutes of incubation with the NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME; 100 mol/L). The NADPH-stimulated superoxide production was estimated 10 minutes after 100 mol/L NADPH was added. Because lucigeninenhanced chemiluminescence favors redox cycling of lucigenin at high concentrations (250 mol/L) and when NADH is used as a substrate, 21 in the present study, we used low lucigenin concentration (5 mol/L) and NADPH as a substrate. 22 
Vasomotor Studies
Endothelium-dependent and endothelium-independent dilatations were assessed in SVs obtained at the time of coronary artery bypass grafting surgery using isometric tension studies. 12 Four rings from each vessel were precontracted with phenylephrine (3ϫ10 Ϫ6 mol/L); then, endothelium-dependent relaxations were quantified with acetylcholine (10 Ϫ9 to 10 Ϫ5 mol/L). Finally, relaxations to the endothelium-independent NO donor sodium nitroprusside (10
mol/L) were evaluated in the presence of L-NAME (100 mol/L) as previously described. 12
Plasma and Vascular 5-MTHF Measurements
Plasma and vascular 5-MTHF levels were determined by highperformance liquid chromatography as previously described. 12 Plasma 5-MTHF is expressed in nanomoles per liter and vascular 5-MTHF as nanomoles per gram of tissue.
Plasma and Vascular tHcy and Sulfur Amino Acid Measurements
Plasma tHcy was measured by a fluorescence polarization immunoassay adapted to the IMx analyzer (Abbott Diagnostics, Abbott Park, IL). Liquid chromatography-mass spectometry/mass spectometry was used for analyzing vascular tHcy and vascular/plasma methionine, cystathionine, total cysteine, and total glutathione concentrations using a modification of a method previously described (for details, see the online Data Supplement). 23 
Determination of Plasma and Vascular Biopterin Levels
Tetrahydrobiopterin (BH4) levels in plasma or vessel tissue lysates were determined by high-performance liquid chromatography, followed by electrochemical detection as previously described. 24 BH4 levels were expressed as picomole per gram of tissue for vessels and nanomole per liter for plasma.
Statistical Analysis
All variables were tested for normal distribution with the Kolmogorov-Smirnov test. Normally distributed variables are presented as meanϮSEM; nonnormally distributed variables were log transformed for analysis and are presented as median (25th to 75th percentiles) and range. Comparisons of baseline and demographic characteristics between the 3 genotypes were performed with 1-way ANOVA, and the unpaired t test was used to compare variables between 2 groups (for recessive models). Two-way ANOVA for repeated measures was used to compare the dose-response vasorelaxation curves between groups. Bivariate analysis was performed by calculation of Pearson's correlation coefficient. Multivariable linear regression analysis was used to examine the effect of vascular 5-MTHF or tHcy levels on L-NAME-induced change in vascular superoxide, NADPHstimulated superoxide, or maximum relaxations of SVs to acetylcholine. These parameters were used as dependent variables; for independent variables, we used those variables of the following list that showed an association with the dependent variable in bivariate analysis at the level of 10%: 5-MTHF (or 677 CϾT genotype), tHcy, age, gender, diabetes mellitus, smoking, dyslipidemia, hypertension, and body mass index. A backward elimination procedure was applied in all models, with PϾ0.1 as a threshold to remove a variable from the model. All probability values were 2 tailed, and values of PϽ0.05 were considered statistically significant. All statistical analyses were performed with SPSS 12.0 (SPSS Inc, Chicago, Ill).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
To establish the relative levels of 5-MTHF and homocysteinerelated compounds in the human vascular wall, we first determined both plasma and vascular tissue levels of 5-MTHF, tHcy, total cysteine, total glutathione, cystathione, and methionine in samples from 218 patients with coronary artery disease ( Table 2) . As expected, plasma tHcy was weakly associated with cystathione (rϭ0.332, Pϭ0.0001) and total cysteine (rϭ0.348, Pϭ0.0001). However, the respective associations were much stronger in vascular tissue than in plasma in both IMAs (rϭ0.744, Pϭ0.0001 for total cysteine; rϭ0. 308 Pϭ0 .09 in IMAs). Taken together, these novel findings support the notion that folate and homocysteine metabolism in the vascular wall behaves as an independent compartment from plasma.
We next evaluated the effect of constitutive alteration of 5-MTHF synthesis, determined by MTHFR 677 CϾT genotype, on both plasma 5-MTHF and plasma tHcy levels. As expected, levels of plasma 5-MTHF and plasma tHcy were significantly associated with MTHFR genotype (Figure 1) . However, the difference in plasma 5-MTHF between MTHFR 677 CC and TT genotypes was proportionately much greater than the corresponding difference in tHcy. Furthermore, in vascular tissue, MTHFR genotype was significantly associated with 5-MTHF but not with tHcy levels (Figure 2 ), suggesting that 5-MTHF may be a less important regulator of tHcy in the vascular wall.
We next used the presence of the MTHFR 677 CϾT polymorphism to test the effects of constitutive differences in vascular 5-MTHF levels, without respective variations of vascular tHcy, on endothelial function, as defined by the vasomotor responses of vascular segments. We observed that the presence of the MTHFR 677 T allele was associated with significantly reduced vasorelaxations in response to acetylcholine, indicative of impaired endothelial function ( Figure  3 ). Vascular 5-MTHF levels were significantly associated with vasomotor responses to acetylcholine (Figure 3) , whereas plasma 5-MTHF levels showed only a borderline association (Pϭ0.07). In addition, neither the MTHFR 677CϾT polymorphism (Figure 3 ) nor vascular (Figure 3 ) or plasma (data not shown) levels of 5-MTHF had any impact on the vasorelaxations in response to sodium nitroprusside. In contrast, neither vascular ( Figure 3 ) nor plasma (data not shown) tHcy levels showed any association with vasorelaxations to acetylcholine or sodium nitroprusside. Thus, the effects of the MTHFR 677 CϾT polymorphism on endothelial function appear to be mediated through vascular levels of 5-MTHF rather than either vascular or plasma tHcy.
To further examine the mechanisms by which 5-MTHF and tHcy affect vascular function, we evaluated their impact on vascular superoxide generation and on the major sources of superoxide in the vascular wall. We observed that the presence of the MTHFR 677 T allele was associated with significantly higher vascular superoxide radical production ( Figure 4 ). To further explore the effect of MTHFR genotype on the individual sources of superoxide radical generation in the vascular wall, we specifically examined the contributions of eNOS uncoupling and NADPH-oxidase activity. We observed that the presence of the T allele was associated with a significantly greater L-NAME-inhibitable superoxide radical generation in IMA segments, suggesting an association between vascular 5-MTHF and eNOS coupling (Figure 4 ). In contrast, there was no detectable effect of the MTHFR 677 T allele on NADPH-stimulated superoxide radical generation in IMA segments (Figure 4) . The presence of the T allele also was associated with significantly lower vascular BH4 in these vessels (Figure 4) .
To determine whether the relationship between the MTHFR 677 CϾT polymorphism and vascular superoxide generation was mediated principally through 5-MTHF or tHcy, we examined the associations between plasma/vascular 5-MTHF or plasma/vascular tHcy and superoxide radical generation. We observed that high plasma 5-MTHF was associated with low vascular superoxide generation ( Figure  5 ) and low L-NAME-inhibitable superoxide generation (FigFigure 1 . The MTHFR 677 CϾT polymorphism was associated with plasma levels of both 5-MTHF (A) and tHcy (B) in patients with atherosclerosis. Analyses were performed by 1-way ANOVA of the log-transformed values. Values are expressed as median (25th to 75th percentile) and range. These measurements were performed in the entire study population. ure 5). However, there was no association between plasma 5-MTHF and NADPH-stimulated vascular superoxide generation ( Figure 5 ). Conversely, plasma tHcy was not associated with vascular superoxide generation or L-NAME-inhibitable or NADPH-stimulated superoxide radical generation. We next examined the corresponding associations with vascular 5-MTHF or tHcy levels. We observed that both vascular 5-MTHF and vascular tHcy were associated with overall vascular superoxide generation ( Figure 6 ). However, high vascular 5-MTHF levels were associated with lower L-NAMEinhibitable superoxide production, indicative of improved eNOS coupling, an effect not observed for vascular tHcy ( Figure 6 ). Conversely, vascular tHcy but not vascular 5-MTHF was significantly associated with NADPH-stimulated superoxide production, suggesting that tHcy is related to NADPHoxidase activity in human vessels ( Figure 6 ).
In a multivariable linear regression analysis in which vascular 5-MTHF and vascular tHcy were considered for inclusion in the same multiple regression models, we observed that vascular 5-MTHF was the only predictor of L-NAME-inhibitable superoxide in IMAs (␤ϭ1. CϾT polymorphism) is principally associated with eNOS uncoupling in human vessels, whereas vascular tHcy is associated with NADPH-induced vascular superoxide generation.
Discussion
In the present study, we have demonstrated that the MTHFR 677 CϾT polymorphism affects plasma levels of both 5-MTHF and tHcy in patients with coronary artery disease. In vascular tissue, however, where the MTHFR 677 CϾT genotype was more strongly associated with 5-MTHF levels than in plasma, there was no association with vascular tHcy levels in the same vessels. Thus, we conclude that the biological effects of the MTHFR 677 CϾT polymorphism in vascular pathophysiology are more likely mediated by effects on 5-MTHF availability rather than by secondary effects on tHcy levels. We substantiated this conclusion by a systematic evaluation of the respective associations between MTHFR 677 CϾT genotype, plasma and vascular tissue levels of both 5-MTHF and tHcy, and aspects of vascular pathophysiology with known importance in vascular disease: NO-mediated endothelial function, vascular superoxide production, and vascular BH4 levels. Whereas the MTHFR 677 CϾT genotype was significantly associated with endothelial function and vascular superoxide production, both univariate and multivariable linear regression analyses revealed associations with vascular 5-MTHF levels but not with vascular tHcy levels. In addition, both 5-MTHF and tHcy are determinants of vascular superoxide radical generation, but 5-MTHF affects mainly eNOS coupling and NO bioavailability, whereas vascular tHcy affects vascular redox state by modifying vascular NADPH-oxidase activity. Taken together, these findings suggest that vascular 5-MTHF and tHcy are independently associated with the vascular redox state by affecting eNOS coupling and NADPH-oxidase activity, respectively.
Elevated plasma tHcy has previously been associated with increased cardiovascular risk. 25 Plasma tHcy has been associated with increased oxidative stress and endothelial dysfunction, 3 suggesting that tHcy is directly implicated in atherogenesis. On the other hand, it is still unclear whether homocysteine-lowering treatment with folate or B vitamins has the potential to alter cardiovascular risk. Despite the well-described decline in cardiovascular risk and the risk of stroke in North America since the introduction of folate food fortification, 26 recent clinical trials failed to demonstrate any effect on cardiovascular risk in secondary prevention in patients with recent myocardial infarction 9 or with stable coronary artery disease living in areas with folate fortification. 10 Therefore, the existing controversy in the field suggests that further investigation of the mechanisms relating tHcy, folates, and cardiovascular disease is inevitable.
Evidence suggests that eNOS coupling plays a key role in maintaining vascular redox equilibrium. 27 We have recently demonstrated that 5-MTHF, the circulating form of folic acid, has the potential to scavenge peroxynitrite radicals inside the vascular wall, thus protecting the oxidative degradation of BH4, an NOS cofactor. 12 In line with our observation, 5-MTHF also was demonstrated to improve endothelial function in several clinical conditions such as established atherosclerosis 28 or renal failure. 13, 14 This direct effect of acute 5-MTHF administration 12 or chronic folate supplementation 29 on vascular BH4 bioavailability appeared to be independent of systemic tHcy lowering. 12, 29 However, despite the direct effect of folate administration on vascular NO bioavailability in patients with coronary artery disease, 12, 29, 30 there are no mechanistic data supporting that endogenous 5-MTHF may affect eNOS coupling and the vascular redox state in humans. Indeed, it is likely that 5-MTHF administration induces a rapid decrease in intracellular tHcy, before any systemic change in tHcy is witnessed. Therefore, it is crucial to define the exact contribution of 5-MTHF and tHcy on vascular function in human atherosclerosis.
To explore the role of 5-MTHF on vascular function, we used the well-known functional 677 CϾT polymorphism in the MTHFR gene as a model system to study the impact of chronic exposure of human vessels to differential levels of 5-MTHF. Evidence suggests that the presence of the T allele is associated with significantly lower plasma 5-MTHF levels and higher plasma tHcy 31 compared with other genotypes, but it is unclear whether this also applies for intravascular folate and homocysteine concentrations. Although MTHFR is responsible for the endogenous synthesis of 5-MTHF from tetrahydrofolate and 5-MTHF is necessary for the conversion of homocysteine back to methionine (by homocysteinemethyltransferase), it is likely that the expression of MTHFR may vary in different cell types in the human body. 32 Indeed, liver is the main contributor of tHcy in the circulation, and the mechanisms controlling intracellular 5-MTHF and therefore affecting its ability to saturate the enzymatic conversion of homocysteine to methionine may be different in liver and vascular endothelium.
In the present study, we demonstrate for the first time that despite the significant effect of the MTHFR 677 CϾT polymorphism on plasma 5-MTHF and tHcy, this polymorphism does not affect vascular tHcy, despite its strong effect on vascular 5-MTHF levels in both human arteries and veins. This is compatible with our previous observation that vascular endothelium behaves as a different compartment than systemic circulation regarding the regulation of 5-MTHF levels. 29 It is likely that endothelial cells express sufficient amounts of MTHFR to maintain the critical intracellular 5-MTHF levels necessary for the normal conversion of tHcy to methionine, even in the presence of the T allele. This hypothesis explains the observation that the presence of the T allele does not affect vascular tHcy levels in human arteries and veins.
We have previously demonstrated that high-dose intravenous administration of 5-MTHF affects eNOS coupling, resulting into an improvement in NO bioavailability and a reduction in superoxide radicals generation in human arteries and veins. 12 We suggested that this effect was due partly to the ability of 5-MTHF to scavenge peroxynitrite radicals in human vessels, thus protecting the oxidation of the eNOS cofactor BH4. 12 However, it was unclear whether physiological variations of endogenous 5-MTHF levels have the potential to define endothelial function in humans. In addition, it was unclear whether 5-MTHF exerts its effects independently of tHcy levels in systemic circulation or in plasma. In the present study, we have demonstrated that resting vascular 5-MTHF levels are strongly associated with total vascular superoxide production and with eNOS coupling in human arteries, whereas they have no effect on NADPHoxidase activity in these vessels. However, vascular but not plasma tHcy had an effect on vascular superoxide production by these vessels, mainly by modifying NADPH-oxidase activity. Most important, the effect of 5-MTHF on eNOS coupling and the effect of vascular tHcy on NADPH-oxidase activity in human arteries were independent of each other, suggesting that 5-MTHF and tHcy exert their effect on the vascular redox state by affecting different enzymatic pathways of superoxide generation.
The finding that vascular tHcy affects superoxide generation in human arteries by modulating NADPH-oxidase activity is consistent with previous observations in cell culture systems, which have demonstrated that incubation of monocytes with homocysteine increases NADPH-oxidase activity by affecting the phosphorylation of p47phox and p67phox subunits of this enzyme, enhancing their translocation to cellular membranes. 33, 34 However, the effect of vascular tHcy on NADPH-oxidase activity does not necessarily lead also to impaired NO bioavailability and endothelial dysfunction, as we have shown in this study.
Because previous reports have suggested that treatment with 5-MTHF 12 or folates 29 improves NO bioavailability in human vessels, we sought to examine whether the same effect is observed for the variations of plasma and vascular 5-MTHF within the normal range. We observed that high plasma or vascular 5-MTHF was associated with better vasorelaxations of SVs in response to acetylcholine compared with low 5-MTHF levels. Most important, neither plasma nor vascular tHcy had any effect on the vasorelaxations in response to acetylcholine, suggesting that variations of tHcy within the normal range have a minor effect on endothelial function in patients with coronary artery disease.
The experiments in the present study were done in SVs and IMAs, both of which do not develop atherosclerosis, although these vessels seem to be reliable model systems to study the mechanisms involved in atherogenesis in humans. Because the present study was done entirely in human vessels, the limited amount of tissue obtained from each patient did not allow every experiment to be done on every vessel, which is a limitation of the study. Furthermore, the vasorelaxation experiments were done in SV samples, but as previously shown, 35 IMAs exhibit much better endothelial function than SVs, and this had been suggested as a mechanism making these vessels resistant to atherosclerosis. 35 Therefore, the absence of further replication of our vasorelaxation findings in IMA points out that extrapolation of these observations to arteries should be made with caution. Another limitation of the study comes from the use of lucigenin-enhanced chemiluminescence to evaluate superoxide generation. Lucigenin-enhanced chemiluminescence favors redox cycling of lucigenin at high concentrations (250 mol/L), 21 a phenomenon that is minimally observed when a low lucigenin concentration (5 mol/L) is used. 21 In addition, lucigenin redox recycling is detectable even at lucigenin concentrations as low as 5 mol/L when NADH is used as a substrate, a phenomenon that is further reduced when NADPH is used as a substrate. 22 Therefore, by using low lucigenin concentrations and NADPH as a substrate in our studies, we reduce these artifacts to the minimum.
Conclusions
Vascular endothelium circulation and systemic circulation behave as independent compartments regarding the metabolism of homocysteine. Despite the strong impact of the MTHFR 677 CϾT polymorphism on vascular and plasma 5-MTHF and on plasma tHcy, it appears to have a minor role in the regulation of vascular tHcy levels in humans. In addition, plasma or circulating 5-MTHF and the MTHFR 677 CϾT polymorphism exert a direct effect on vascular BH4 levels, NO bioavailability, and eNOS coupling in human vessels in vivo, whereas vascular but not plasma tHcy is a regulator of vascular NADPH-oxidase activity. Therefore, 5-MTHF and tHcy have independent effects on the vascular redox state by affecting different enzymatic sources of superoxide such as uncoupled eNOS or NADPH-oxidase.
